Savara has concluded its Phase I studies of AeroVancâ„¢, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile. We are conducting a Phase IIa trial at multiple sites across the U.S. Click here to learn more.

AeroVanc phase I

Savara has concluded its Phase I studies of AeroVancâ„¢, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile.

 

AeroVanc Phase II

Savara is now enrolling CF patients in a multicenter study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection. The trial is being conducted in 40 sites throughout the U.S.